Your browser doesn't support javascript.
loading
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
Park, See-Hyoung; Chung, Young Min; Ma, Jessica; Yang, Qin; Berek, Jonathan S; Hu, Mickey C-T.
Affiliation
  • Park SH; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Chung YM; Current address: Department of Biological and Chemical Engineering, Hongik University, Sejong, 339-701, Korea.
  • Ma J; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Yang Q; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA.
  • Berek JS; Cancer Biology Division, Department of Radiation Oncology, Washington University School of Medicine, Saint Louis, MO 63108, USA.
  • Hu MC; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305, USA.
Oncotarget ; 7(27): 42110-42125, 2016 Jul 05.
Article in En | MEDLINE | ID: mdl-27283899
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Breast Neoplasms / Gene Silencing / Triple Negative Breast Neoplasms / Forkhead Box Protein O3 Limits: Animals / Female / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 6_ODS3_enfermedades_notrasmisibles Database: MEDLINE Main subject: Breast Neoplasms / Gene Silencing / Triple Negative Breast Neoplasms / Forkhead Box Protein O3 Limits: Animals / Female / Humans Language: En Journal: Oncotarget Year: 2016 Document type: Article